Hormonal
Genetic variation in the GLP1R locus is associated with cardiometabolic traits (BMI, blood pressure, type 2 diabetes) across diverse ancestries, but these variants do not influence GLP1R gene expression in a way that explains mental ill-health (MIH) endophenotypes.
If you are taking or considering GLP-1 receptor agonists (like semaglutide or tirzepatide) for weight loss or diabetes, be aware that any mental health benefits you experience are likely not due to the drug acting directly on your GLP-1 receptors. Genetic evidence suggests these behavioral effects operate through different mechanisms, possibly involving other genes or secondary metabolic improvements.
The meta-analysis showed consistent effects of GLP1R on CMt across ancestries but inconsistent effects on MIH. Seven lead variants were associated with MIH endophenotypes, but none influenced GLP1R expression, suggesting that effects of GLP1R variants on MIH are likely not acting through GLP1R.
Why this rating
Large sample size (UK Biobank, N > 400,000) and trans-ancestry meta-analysis provide robust statistical power, though it is observational genetic data, not an RCT.
Source
Association of <scp> <i>GLP1R</i> </scp> locus with mental ill‐health endophenotypes and cardiometabolic traits: A trans‐ancestry study in <scp>UK</scp> Biobank
Madeleine M. E. Hayman et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16178
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →